Canbex Therapeutics has completed a 2.1m ($3.2m) fundraising round to complete early development of drug candidate to treat spasticity in multiple sclerosis (MS). The financing for the round was led by Merck Serono Ventures, the venture ...
Tags: Canbex Therapeutics, Canbex